GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Stallergenes Greer PLC (GREY:STLLF) » Definitions » Forward PE Ratio

Stallergenes Greer (Stallergenes Greer) Forward PE Ratio : 0.00 (As of May. 23, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Stallergenes Greer Forward PE Ratio?

Stallergenes Greer's Forward PE Ratio for today is 0.00.

Stallergenes Greer's PE Ratio without NRI for today is 56.46.

Stallergenes Greer's PE Ratio (TTM) for today is 56.46.


Stallergenes Greer Forward PE Ratio Historical Data

The historical data trend for Stallergenes Greer's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stallergenes Greer Forward PE Ratio Chart

Stallergenes Greer Annual Data
Trend
Forward PE Ratio

Stallergenes Greer Semi-Annual Data
Forward PE Ratio

Competitive Comparison of Stallergenes Greer's Forward PE Ratio

For the Biotechnology subindustry, Stallergenes Greer's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Stallergenes Greer's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Stallergenes Greer's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Stallergenes Greer's Forward PE Ratio falls into.



Stallergenes Greer Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Stallergenes Greer  (GREY:STLLF) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Stallergenes Greer Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Stallergenes Greer's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Stallergenes Greer (Stallergenes Greer) Business Description

Traded in Other Exchanges
N/A
Address
40 Bernard Street, 3rd Floor, London, GBR, WC1N 1LE
Stallergenes Greer PLC is a pharmaceutical company. The company treats severe allergic rhinitis with allergen immunotherapy. Its portfolio comprises of Sublingual products, Subcutaneous products, Veterinary products and Other. The sublingual products are offered under the brand name Staloral and Oralair. The Subcutaneous products include Phostal, Alustal, Alyostal, Albey. The company also offers enzyme-linked immunosorbent assay components and prescription services. It provides skin testing devices enabling the identification of the allergen or allergens responsible for the allergy, sterile diluents and sterile empty vials, syringes, and other compendial products. The company operates in internationally and geographically generates maximum revenue from the United States.

Stallergenes Greer (Stallergenes Greer) Headlines

No Headlines